What Sinclair Pharma plc does

Sinclair Pharma plc is a global medical aesthetics company headquartered in London, United Kingdom, that manufactures and commercializes a portfolio of injectable and energy-based device (EBD) treatments for healthcare professionals and aesthetic clinics. The injectable line spans HA fillers (MaiLi portfolio of four products, Perfectha) and biostimulator/collagen-stimulating treatments (Ellansé, Lanluma). The energy-based device line covers body contouring (Cooltech, Cooltech Define, Sculpt&Shape) and skin/laser platforms (Primelase Excellence, Elysion Pro, V-SERIES, Reaction). Products are sold through direct commercial operations in Europe, MEA, Brazil, North America, and Singapore, supplemented by a distributor network that extends reach to more than 55 countries.

The company pursues a B2B go-to-market: it sells devices and consumables to physicians and clinics rather than directly to consumers, and supports adoption through dedicated healthcare professional education platforms (Sinclair College, Sinclair Portal, RISE). Sinclair has grown materially through M&A, executing multi-asset acquisition programs in 2014 (SilhouetteLift, AQTIS Medical, Atlean, ObvieLine Laboratories), 2017 (Refine LLC), and most recently in February 2022 with the acquisition of Viora, which was folded into the EBD portfolio to strengthen US market position. Since 2018, Sinclair has operated as a wholly owned subsidiary of Huadong Medicine Company Limited (Hangzhou, China), a strategic Chinese pharmaceutical parent also known as East China Pharmaceuticals or HMC, following a take-private transaction.

The business is run as a focused, pure-play aesthetics platform within the larger Huadong group, leveraging parent-company capital for inorganic expansion. Customer concentration is structurally low given the long-tail distribution model across 55+ countries, and competitive position rests on a regulated, multi-brand product portfolio, practitioner training infrastructure, and global commercial reach rather than technology platforms or software.

Name

Sinclair Pharma plc

Legal name

Sinclair Pharma plc

Website

https://sinclairpharma.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sinclair Pharma plc is a London-headquartered global medical aesthetics company that manufactures and sells injectable treatments (MaiLi, Ellansé, Lanluma, Perfectha) and energy-based devices (Cooltech, Primelase, Elysion Pro, V-SERIES) to healthcare professionals and clinics across more than 55 countries, operating as a wholly owned subsidiary of Huadong Medicine.

Ownership category

akta.pro rank

Product category

Medical Aesthetics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK)

Keywords

• Medical aesthetics
• Injectable treatments
• Energy-based devices
• Hyaluronic acid fillers
• Body contouring devices

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Medical Aesthetics Products: Manufacturing and commercializing a wide portfolio of injectable and energy-based device (EBD) treatments for medical aesthetics. Revenue generated through product sales to healthcare professionals and clinics.
2. Acquisition Integration: Sinclair integrates acquired companies into its portfolio, such as Viora merging into the Energy-Based Devices portfolio, expanding product offerings and market reach.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Sinclair Pharma manufactures and commercializes a global portfolio of injectable aesthetic treatments (hyaluronic acid fillers and collagen stimulators including MaiLi, Ellansé, Lanluma, Perfectha) and energy-based devices (Cooltech, Elysion Pro, Primelase Excellence, Reaction, Sculpt&Shape, V-SERIES) for body contouring and skin rejuvenation, sold to healthcare professionals and clinics in 55+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• MaiLi: Portfolio of four advanced HA (hyaluronic acid) fillers designed for facial rejuvenation
• Lanluma
• Ellansé
• Perfectha
• Cooltech
• Cooltech Define
• Elysion Pro
• Primelase Excellence
• Reaction
• Sculpt&Shape
• V-SERIES
• Sinclair College
• Sinclair Portal
• RISE

Products and services

• MaiLi Portfolio of four advanced hyaluronic acid (HA) fillers designed to enable physicians to deliver facial aesthetic treatments with precision.
• Lanluma Injectable aesthetic treatment product used by healthcare professionals for facial and body volumisation.
• Ellansé Injectable aesthetic treatment product based on collagen stimulation, used by physicians for facial rejuvenation and volumisation.
• Perfectha Injectable aesthetic treatment product for facial aesthetic procedures performed by medical professionals.
• Cooltech Energy-based device for non-invasive body contouring treatments, used by aesthetic clinics and physicians.
• Cooltech Define Energy-based device for body contouring treatments, used by aesthetic clinics and physicians.
• Elysion Pro Energy-based device used by aesthetic clinics for skin rejuvenation and aesthetic treatments.
• Primelase Excellence Energy-based device (laser hair removal platform) used by aesthetic clinics for hair removal and related treatments.
• Reaction Energy-based device used by aesthetic clinics for body contouring and skin treatments.
• Sculpt&Shape Energy-based device for non-invasive body shaping treatments, used by aesthetic clinics.
• V-SERIES Energy-based device product line for aesthetic treatments, used by clinics and physicians.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

One partnership is on record.

• VioracoreStrategic or Co-development Partner · 4 February 2022Viora, a medical aesthetic device company, was acquired by Sinclair Pharma and merged into Sinclair's Energy-Based Devices portfolio. The acquisition aims to expand Sinclair's global presence and product offerings in the aesthetic market, particularly strengthening its position in the United States.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Teoxane: Swiss aesthetics company focused on premium HA fillers (TEOSYAL RHA range) — a close direct competitor to Sinclair's MaiLi and Perfectha HA filler lines, especially in Europe and Asia.
• Croma-Pharma: Austrian aesthetics company selling HA fillers (Princess/HArmonyCA) and regenerative/thread products — comparable mid-sized specialist competing with Sinclair's injectable portfolio in European and international markets.
• Merz Aesthetics: Specialist aesthetics business selling Belotero HA fillers, Radiesse biostimulator, and Ultherapy energy-based skin lifting — directly competes with Sinclair's MaiLi/Ellansé injectable line and EBD portfolio in physician channels globally.
• BTL Aesthetics: Energy-based device company behind Emsculpt body contouring, Emface facial toning, and Exilis — directly comparable to Sinclair's Cooltech/Cooltech Define and Sculpt&Shape body-shaping devices, competing for the same physician accounts.
• Alma Lasers: Global aesthetics/Surgical EBD manufacturer with platforms across hair removal, body contouring, and skin rejuvenation — broad EBD portfolio directly comparable to Sinclair's multi-brand EBD offering.
• Cynosure (Hologic): Energy-based aesthetics device manufacturer (TempSure, Potenza, MonaLisa Touch) now part of Hologic — directly competes with Sinclair's Elysion Pro, Primelase Excellence, and Reaction aesthetic device platforms in clinics and medspas.
• Galderma: Global pure-play dermatology/aesthetics company marketing Restylane HA fillers, Sculptra biostimulator, and complementary skincare — directly comparable to Sinclair's Ellansé, Perfectha, and MaiLi franchises and serving the same physicians and clinics.

Broad incumbents

• Allergan Aesthetics (AbbVie): Aesthetics arm of AbbVie marketing Juvéderm HA fillers, Botox, and CoolSculpting body contouring — overlaps Sinclair across injectables (vs Juvéderm/MaiLi/Perfectha) and energy-based body contouring (CoolSculpting vs Cooltech/Cooltech Define), with much broader scale and pipeline.

Emerging players

• Revance Therapeutics: Aesthetics-focused biotech marketing Daxify neurotoxin and the RHA Collection of HA fillers (via Teoxane partnership) — an emerging injectables player with a more limited geographic footprint but overlapping injectable competition with Sinclair.
• Hugel (Charmmed): Korean aesthetics company with Botulax neurotoxin and a growing filler/device line, expanding internationally — an emerging Asian-rooted competitor relevant to Sinclair's Huadong-driven APAC positioning and overlapping injectable categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinclair Pharma plc